AveXis (AVXS) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of AveXis (NASDAQ:AVXS) from a sell rating to a hold rating in a research report released on Tuesday.

According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “

A number of other research analysts also recently issued reports on AVXS. Royal Bank of Canada started coverage on AveXis in a report on Thursday, September 14th. They issued a sector perform rating and a $92.00 price target on the stock. Wells Fargo & Co reiterated an outperform rating on shares of AveXis in a report on Friday, September 29th. BMO Capital Markets reiterated an outperform rating and issued a $123.00 price target on shares of AveXis in a report on Saturday, September 30th. Citigroup lifted their price target on AveXis from $100.00 to $116.00 and gave the company a buy rating in a report on Monday, October 2nd. Finally, UBS Group reiterated a buy rating and issued a $122.00 price target (up from $95.00) on shares of AveXis in a report on Tuesday, October 3rd. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the stock. AveXis has an average rating of Buy and a consensus price target of $111.67.

AveXis (NASDAQ AVXS) opened at $117.50 on Tuesday. AveXis has a fifty-two week low of $50.56 and a fifty-two week high of $119.00.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the firm posted ($0.87) earnings per share. research analysts anticipate that AveXis will post -6.23 EPS for the current year.

In other news, VP Andrew F. Knudten sold 2,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total value of $188,960.00. Following the completion of the sale, the vice president now owns 7,000 shares of the company’s stock, valued at approximately $661,360. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the completion of the sale, the insider now directly owns 1,841,019 shares of the company’s stock, valued at approximately $186,366,353.37. The disclosure for this sale can be found here. Insiders sold a total of 52,340 shares of company stock valued at $5,318,845 in the last three months. Insiders own 18.60% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in shares of AveXis in the 3rd quarter worth $116,000. Ameritas Investment Partners Inc. lifted its position in AveXis by 331.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after acquiring an additional 1,622 shares during the period. Cubist Systematic Strategies LLC lifted its position in AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after acquiring an additional 1,577 shares during the period. Teacher Retirement System of Texas acquired a new stake in AveXis during the 3rd quarter worth about $200,000. Finally, Deschutes Portfolio Strategy LLC acquired a new stake in AveXis during the 3rd quarter worth about $203,000. 92.88% of the stock is owned by hedge funds and other institutional investors.

WARNING: “AveXis (AVXS) Upgraded at Zacks Investment Research” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/01/13/avexis-avxs-upgraded-at-zacks-investment-research.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get a free copy of the Zacks research report on AveXis (AVXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply